Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154047 · ClinicalTrials.gov registry record · Phase 2
Study in Subjects With Light Chain (AL) Amyloidosis
A Phase 2 study, sponsored by Prothena Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03154047 is a Phase 2 study that was terminated before completion, run by Prothena Biosciences. The registered enrollment target is 80 participants.
The verdict
NCT03154047, a Phase 2 study, was terminated before completion, sponsored by Prothena Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
Interventions
- DRUG NEOD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154047
The ClinicalTrials.gov registry entry for NCT03154047 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prothena Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NEOD001 is the first listed.
NCT03154047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03154047 about?
NCT03154047 is a clinical study titled "Study in Subjects With Light Chain (AL) Amyloidosis". The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
What is the current status of trial NCT03154047?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-06-14. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT03154047?
The interventions under investigation include: NEOD001 (DRUG).
Who is sponsoring clinical trial NCT03154047?
This trial is sponsored by Prothena Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.